Signal transduction pathways of the human V1-vascular, V2-renal, V3-pituitary vasopressin and oxytocin receptors

被引:0
|
作者
Thibonnier, M
Berti-Mattera, LN
Dulin, N
Conarty, DM
Mattera, R
机构
[1] Case Western Reserve Univ, Sch Med, Dept Med, Cleveland, OH 44106 USA
[2] Case Western Reserve Univ, Sch Med, Dept Physiol, Cleveland, OH 44106 USA
来源
关键词
D O I
暂无
中图分类号
Q189 [神经科学];
学科分类号
071006 ;
摘要
Vasopressin (VP) and oxytocin (OT) are cyclic nonapeptides whose actions are mediated by stimulation of specific G protein-coupled receptors (GPCRs) currently classified into V-1-vascular (V1R), V-2-renal (V2R) and V-3-pituitary (V3R) VP receptors and OT receptors (OTR). The recent cloning of the different members of the VP/OT family of receptors now allows the extensive characterization of the molecular determinants involved in ligand binding and signal transduction pathways coupled to a given VP/OT receptor subtype in stably transfected mammalian cell lines. In this article, we review the present knowledge of the signal transduction pathways coupled to the different VP/ OT receptor subtypes and we present new observations derived from the study of each human VP or OT receptor subtype stably expressed in CHO cells.
引用
收藏
页码:147 / 161
页数:15
相关论文
共 50 条
  • [31] V1-VASCULAR AVP RECEPTORS ACTIVATE THE ARACHIDONIC-ACID EPOXYGENASE PATHWAY
    THIBONNIER, M
    BAYER, AL
    KOOP, DR
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 1992, 51 (02) : 171 - 171
  • [32] Oxytocin induces social communication by activating arginine-vasopressin V1a receptors and not oxytocin receptors
    Song, Zhimin
    McCann, Katharine E.
    McNeill, John K.
    Larkin, Tony E., II
    Huhman, Kim L.
    Albers, H. Elliott
    PSYCHONEUROENDOCRINOLOGY, 2014, 50 : 14 - 19
  • [33] VASOPRESSIN V-1 AND V-2 RECEPTORS IN DIABETES-MELLITUS
    TRINDER, D
    PHILLIPS, PA
    STEPHENSON, JM
    RISVANIS, J
    AMINIAN, A
    ADAM, W
    COOPER, M
    JOHNSTON, CI
    AMERICAN JOURNAL OF PHYSIOLOGY, 1994, 266 (02): : E217 - E223
  • [34] Molecular modeling of interactions of the non-peptide antagonist YM087 with the human vasopressin V1a, V2 receptors and with oxytocin receptors.
    Gieldon, A
    Kazmierkiewicz, R
    Slusarz, R
    Ciarkowski, J
    JOURNAL OF COMPUTER-AIDED MOLECULAR DESIGN, 2001, 15 (12) : 1085 - 1104
  • [35] Mapping peptide antagonist binding sites of the human V1a and V2 vasopressin receptors
    Mouillac, B
    Phalipou, S
    Cotte, N
    Balestre, MN
    Hibert, M
    Manning, M
    Barberis, C
    VASOPRESSIN AND OXYTOCIN: MOLECULAR, CELLULAR, AND CLINICAL ADVANCES, 1998, 449 : 359 - 361
  • [36] Molecular modeling of interactions of the non-peptide antagonist YM087 with the human vasopressin V1a, V2 receptors and with oxytocin receptors.
    Artur Giełdoń
    Rajmund Kaźmierkiewicz
    Rafał Ślusarz
    Jerzy Ciarkowski
    Journal of Computer-Aided Molecular Design, 2001, 15 : 1085 - 1104
  • [37] Functional characterization of vasopressin V1 and V2 receptors in the rabbit renal cortical collecting duct
    Yoshitomi, K
    Naruse, M
    Hanaoka, K
    Yamamura, Y
    Imai, M
    Kurokawa, K
    KIDNEY INTERNATIONAL, 1996, : S177 - S182
  • [38] Selective Blockade of Oxytocin and Vasopressin V1a Receptors in Anaesthetised Rats: Evidence that Activation of Oxytocin Receptors rather than V1a Receptors Increases Sodium Excretion
    Shirley, D. G.
    Walter, M. F.
    Keeler, B. D.
    Waters, N. J.
    Walter, S. J.
    NEPHRON PHYSIOLOGY, 2011, 117 (03): : P21 - P26
  • [39] Immunocytochemical localization of vasopressin V1a receptors in the rat pituitary gonadotropes
    Orcel, H
    Tobin, VA
    Alonso, G
    Rabié, A
    ENDOCRINOLOGY, 2002, 143 (11) : 4385 - 4388
  • [40] Role of the human V1 vasopressin receptor COOH terminus in internalization and mitogenic signal transduction
    Thibonnier, M
    Plesnicher, CL
    Berrada, K
    Berti-Mattera, L
    AMERICAN JOURNAL OF PHYSIOLOGY-ENDOCRINOLOGY AND METABOLISM, 2001, 281 (01): : E81 - E92